94
In Germany, new measures have come into effect as part of the GKV-FinStG Act in 2022 that put into question this market’s desirability for orphan drug developers. Similarly, Germany’s Institute for Quality and Efficiency in Healthcare (IQWiG) recently published its analysis regarding the price impact on orphan drugs after an abridged assessment and subsequent full benefit. GlobalData has therefore taken the opportunity to assess the current situation of orphan drugs in the German oncology market. To gain…